PL02.01 Overall Survival With Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results From PACIFIC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.010
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Brief Report: Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC - Update From PACIFIC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2020English

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab in Patients With Unresectable Stage III NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Durvalumab Extends OS in NSCLC

Cancer Discovery
Oncology
2018English

Improved Overall Survival in Patients With Grade III and IV Acute Graft-Versus-Host Disease

Biology of Blood and Marrow Transplantation
TransplantationHematology
2014English

Better Overall Survival With Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

PD-L1-Antikörper Durvalumab Verlängert Überleben Bei NSCLC Im Stadium III

Pneumologie
MedicinePulmonaryRespiratory Medicine
2018English

122P Pathological Response Rates After Induction Radio-Chemotherapy in Stage III NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Oncologic Outcomes of Postoperative Chemoradiotherapy Versus Chemotherapy Alone in Stage II and III Upper Rectal Cancer

Annals of Coloproctology
Gastroenterology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy